IN2014DN01791A - - Google Patents

Info

Publication number
IN2014DN01791A
IN2014DN01791A IN1791DEN2014A IN2014DN01791A IN 2014DN01791 A IN2014DN01791 A IN 2014DN01791A IN 1791DEN2014 A IN1791DEN2014 A IN 1791DEN2014A IN 2014DN01791 A IN2014DN01791 A IN 2014DN01791A
Authority
IN
India
Prior art keywords
prevention
treatment
invention concerns
receptor antagonists
ampa receptor
Prior art date
Application number
Other languages
English (en)
Inventor
Klaus Kucher
Donald Johns
George Imbert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN01791A publication Critical patent/IN2014DN01791A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1791DEN2014 2011-09-07 2011-09-07 IN2014DN01791A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/050687 WO2013036224A1 (fr) 2011-09-07 2011-09-07 Utilisation de 1h-quinazoline-2,4-diones dans la prévention ou le traitement de l'épilepsie photosensible

Publications (1)

Publication Number Publication Date
IN2014DN01791A true IN2014DN01791A (fr) 2015-05-15

Family

ID=44652020

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1791DEN2014 IN2014DN01791A (fr) 2011-09-07 2011-09-07

Country Status (10)

Country Link
EP (1) EP2753331A1 (fr)
JP (1) JP2014525474A (fr)
KR (1) KR20140071405A (fr)
CN (1) CN103889427A (fr)
AU (1) AU2011376333A1 (fr)
BR (1) BR112014005210A2 (fr)
CA (1) CA2846503A1 (fr)
IN (1) IN2014DN01791A (fr)
MX (1) MX2014002693A (fr)
WO (1) WO2013036224A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物
BR112018012870A2 (pt) 2015-12-30 2018-12-04 Adamas Pharmaceuticals Inc métodos e composições para o tratamento de transtornos relacionados à crise

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
JP2007510645A (ja) 2003-10-31 2007-04-26 アストラゼネカ アクチボラグ アルキン類i
CA2549965A1 (fr) 2003-10-31 2005-05-19 Astrazeneca Ab Alcynes iii
CA2549969A1 (fr) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
AU2005215379A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
RU2008129622A (ru) 2005-12-20 2010-01-27 Новартис АГ (CH) Производные никотиновой кислоты в качестве модуляторов метаботропных глутаматных рецепторов
WO2011055385A1 (fr) * 2009-11-03 2011-05-12 Lupin Limited Préparation de lacosamide à libération modifiée

Also Published As

Publication number Publication date
JP2014525474A (ja) 2014-09-29
EP2753331A1 (fr) 2014-07-16
WO2013036224A1 (fr) 2013-03-14
BR112014005210A2 (pt) 2017-03-21
AU2011376333A1 (en) 2014-03-13
CA2846503A1 (fr) 2013-03-14
MX2014002693A (es) 2014-06-04
CN103889427A (zh) 2014-06-25
KR20140071405A (ko) 2014-06-11

Similar Documents

Publication Publication Date Title
HUS2000032I1 (hu) Helyettesített 4-fenil-piridinek NK-1 receptorral kapcsolatos betegségek kezelésére
GB201017345D0 (en) Receptor antagonists
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
PL3130592T3 (pl) Analogi związków 4h-pirazolo[1,5-α]benzimidazolowych jako inhibitory PARP
PT3242666T (pt) Composto para utilização no tratamento de patologias relacionadas com o recetor s1p1
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
PL2763527T3 (pl) Sposób obróbki grzybobójczej odpornych szczepów przy użyciu jednego lub więcej olejków eterycznych
FR2979931B1 (fr) Potelet de garde-corps ou d'echafaudage equipe d'un bloqueur perfectionne
PL2807170T3 (pl) Limonoidy fragmaliny do leczenia dysfunkcji seksualnych
HUE045270T2 (hu) FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
PH12018500282A1 (en) Cgrp receptor antagonists
EP2771346A4 (fr) Antagonistes des récepteurs d'orexine de type isoxazolopyridine
IN2014KN02993A (fr)
AP2012006630A0 (en) Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin B1 receptor
IN2014DN00254A (fr)
GB2499487B (en) Floating-point of the invention
IN2014DN01791A (fr)
SG10201403562UA (en) Implant for the treatment or prevention of an aneurysm
GB201012359D0 (en) Invention 6.5.10
WO2013130501A8 (fr) Modulateurs bivalents allostériques positifs des récepteurs ampa
FR2996871B1 (fr) Dispositif de correction de la courbure d'une dalle de plancher
IN2012DN00235A (fr)
MX2015001134A (es) Compuestos terapeuticos.
GB201015621D0 (en) Invention 30.08.10